

Special Issue

CAR T Cell Therapy in Cancer: Progress and Challenges Across Solid and Hematologic Malignancies

Message from the Guest Editors

Chimeric Antigen Receptor (CAR) T cell therapy has demonstrated remarkable clinical success in the treatment of several hematologic malignancies, leading to durable remissions in patients with otherwise refractory disease. Despite these successes, translating this approach to solid tumors has proven significantly more complex. Barriers such as poor T cell infiltration, antigen heterogeneity, and the immunosuppressive tumor microenvironment continue to hinder efficacy in solid tumors. Meanwhile, resistance and relapse remain concerns even in hematologic settings, underscoring the need for continued innovation and mechanistic insight across cancer types. This Special Issue aims to explore the evolving field of CAR T-cell therapy across both solid and blood cancers. We invite contributions that address key challenges, novel engineering approaches, strategies to overcome resistance mechanisms, and emerging clinical applications. By bringing together experts from across the CAR T cell therapy landscape, we aim to highlight the progress made and the ongoing challenges that must be addressed to expand the therapeutic impact of CAR T cells across the full spectrum of malignancies.

Guest Editors

Prof. Dr. John F. Marshall

Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK

Dr. Lauren C. Cutmore

Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK

Deadline for manuscript submissions

31 August 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/251808

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)